跳转至内容
Merck
CN

N-049

Supelco

(±)-Norsertraline hydrochloride solution

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H16Cl3N
CAS号:
分子量:
328.66
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

100 μg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

N[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C3=C1C=CC=C3.[H]Cl

InChI

1S/C16H15Cl2N.ClH/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13;/h1-5,7,9,11,16H,6,8,19H2;1H/t11-,16-;/m0./s1

InChI key

YKXHIERZIRLOLD-RISSCEEYSA-N

一般描述

Norsertraline is a major urinary metabolite and N-desmethyl analog of the SSRI antidepressant sertraline. Marketed under trade names such as Zoloft® and Lustral, sertraline is used to treat major depressive, obsessive-compulsive and panic and social anxiety disorders in both adults and children.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zoloft is a registered trademark of Pfizer, Inc.

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Margareta Reis et al.
Journal of affective disorders, 82(3), 443-446 (2004-11-24)
A recent estimation in a psychiatric cohort showed numbers of noncompliance between 10% and 60%. Therapeutic drug monitoring (TDM) is one method assessing compliance by analysis of drug concentration in the blood. During a 24-week phase IV clinical trial, five
N Epperson et al.
The American journal of psychiatry, 158(10), 1631-1637 (2001-10-02)
Pharmacological treatment of postpartum depression is frequently complicated by the mother's desire to breast-feed. Although breast milk levels of several selective serotonin reuptake inhibitors (SSRIs) have been reported to be relatively low, a critical question is whether SSRI exposure during
Margareta Reis et al.
Human psychopharmacology, 19(5), 283-291 (2004-07-15)
Sertraline and paroxetine are frequently prescribed SSRIs for long-term treatment of major depression. Nevertheless, continuous follow-ups of drug concentrations prevailing in patients during the whole treatment period are not available. Hence, in a large phase IV clinical trial, a total
W Ross Tracey et al.
American journal of physiology. Heart and circulatory physiology, 285(6), H2780-H2787 (2003-08-16)
We recently reported the identification of a novel human adenosine A3 receptor-selective agonist, (2S,3S,4R,5R)-3-amino-5-[6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamino]purin-9-yl]-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide (CP-608,039), with 1,260-fold selectivity for the human A3 versus human A1 receptor (DeNinno et al., J Med Chem 46: 353-355, 2003). However, because the
Sarah M R Wille et al.
Journal of chromatography. A, 1098(1-2), 19-29 (2005-11-30)
A solid phase extraction procedure (SPE) for 13 'new' antidepressants (venlafaxine, fluoxetine, viloxazine, fluvoxamine, mianserin, mirtazapine, melitracen, reboxetine, citalopram, maprotiline, sertraline, paroxetine and trazodone) together with eight of their metabolites (O-desmethylvenlafaxine, norfluoxetine, desmethylmianserine, desmethylmirtazapine, desmethylcitalopram, didesmethylcitalopram, desmethylsertraline and m-chlorophenylpiperazine) from

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门